CY1119109T1 - Συσκευη που μπορει να εμφυτευθει που περιεχει υλικο μητρας που μπορει να απορροφηθει και ραπαμυκινη για την προληψη ή την θεραπεια αγγειο-πολλαπλασιαστικων ασθενειων - Google Patents

Συσκευη που μπορει να εμφυτευθει που περιεχει υλικο μητρας που μπορει να απορροφηθει και ραπαμυκινη για την προληψη ή την θεραπεια αγγειο-πολλαπλασιαστικων ασθενειων

Info

Publication number
CY1119109T1
CY1119109T1 CY20171100399T CY171100399T CY1119109T1 CY 1119109 T1 CY1119109 T1 CY 1119109T1 CY 20171100399 T CY20171100399 T CY 20171100399T CY 171100399 T CY171100399 T CY 171100399T CY 1119109 T1 CY1119109 T1 CY 1119109T1
Authority
CY
Cyprus
Prior art keywords
rapamykin
absorpted
implied
appliance
prevention
Prior art date
Application number
CY20171100399T
Other languages
English (en)
Inventor
Sriram S Iyer
Nicholas N Kipshidze
Victor V Nikolaychik
Original Assignee
Vascular Therapies, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vascular Therapies, Llc filed Critical Vascular Therapies, Llc
Publication of CY1119109T1 publication Critical patent/CY1119109T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/225—Fibrin; Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3621—Extra-corporeal blood circuits
    • A61M1/3653—Interfaces between patient blood circulation and extra-corporal blood circuit
    • A61M1/3655—Arterio-venous shunts or fistulae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
    • A61M39/02—Access sites
    • A61M39/0247—Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
    • A61M39/02—Access sites
    • A61M39/0247—Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body
    • A61M2039/0258—Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body for vascular access, e.g. blood stream access
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
    • A61M39/02—Access sites
    • A61M39/0247—Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body
    • A61M2039/0261—Means for anchoring port to the body, or ports having a special shape or being made of a specific material to allow easy implantation/integration in the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0468—Liquids non-physiological
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0468—Liquids non-physiological
    • A61M2202/0478—Heparin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Surgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Composite Materials (AREA)
  • Materials Engineering (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Materials For Medical Uses (AREA)
  • Prostheses (AREA)

Abstract

Μία μέθοδος πρόληψης ή θεραπεία αγγείο-πολλαπλασιαστικής ασθένειας σε αγγειακές δομές, που περιλαμβάνει το βήμα: χορήγησης έξω-αγγειακά και τοπικά μιας αντί-πολλαπλασιαστικής αποτελεσματικής ποσότητας ραπαμυκίνης στην αγγειακή δομή.
CY20171100399T 2001-01-16 2017-04-04 Συσκευη που μπορει να εμφυτευθει που περιεχει υλικο μητρας που μπορει να απορροφηθει και ραπαμυκινη για την προληψη ή την θεραπεια αγγειο-πολλαπλασιαστικων ασθενειων CY1119109T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26213201P 2001-01-16 2001-01-16
EP02718844A EP1351681B1 (en) 2001-01-16 2002-01-16 Implantable device containing resorbable matrix material and anti-proliferative drugs for preventing or treating failure of hemodialysis vascular access and other vascular grafts

Publications (1)

Publication Number Publication Date
CY1119109T1 true CY1119109T1 (el) 2018-02-14

Family

ID=22996277

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100399T CY1119109T1 (el) 2001-01-16 2017-04-04 Συσκευη που μπορει να εμφυτευθει που περιεχει υλικο μητρας που μπορει να απορροφηθει και ραπαμυκινη για την προληψη ή την θεραπεια αγγειο-πολλαπλασιαστικων ασθενειων

Country Status (18)

Country Link
US (5) US6726923B2 (el)
EP (2) EP2314293B1 (el)
JP (2) JP4584537B2 (el)
CN (1) CN1492759A (el)
AP (1) AP2003002828A0 (el)
AT (1) ATE481097T1 (el)
AU (1) AU2002249958B2 (el)
BR (1) BR0206464A (el)
CA (1) CA2434972C (el)
CY (1) CY1119109T1 (el)
DE (1) DE60237671D1 (el)
DK (1) DK2314293T3 (el)
ES (1) ES2621652T3 (el)
MX (1) MXPA03006315A (el)
NZ (1) NZ527046A (el)
PT (1) PT2314293T (el)
RU (1) RU2345719C2 (el)
WO (1) WO2002062335A2 (el)

Families Citing this family (179)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7963997B2 (en) 2002-07-19 2011-06-21 Kensey Nash Corporation Device for regeneration of articular cartilage and other tissue
US8795242B2 (en) * 1994-05-13 2014-08-05 Kensey Nash Corporation Resorbable polymeric device for localized drug delivery
US8697108B2 (en) * 1994-05-13 2014-04-15 Kensey Nash Corporation Method for making a porous polymeric material
DE69734060T2 (de) * 1996-05-24 2006-06-29 Angiotech Pharmaceuticals, Inc., Vancouver Zubereitungen und verfahren zur behandlung oder prävention von krankheiten der körperpassagewege
US7959664B2 (en) * 1996-12-26 2011-06-14 Medinol, Ltd. Flat process of drug coating for stents
US20030129215A1 (en) * 1998-09-24 2003-07-10 T-Ram, Inc. Medical devices containing rapamycin analogs
US6890546B2 (en) 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US7399480B2 (en) * 1997-09-26 2008-07-15 Abbott Laboratories Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
US8057816B2 (en) * 1997-09-26 2011-11-15 Abbott Laboratories Compositions and methods of administering paclitaxel with other drugs using medical devices
US8257726B2 (en) * 1997-09-26 2012-09-04 Abbott Laboratories Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices
US20030040790A1 (en) * 1998-04-15 2003-02-27 Furst Joseph G. Stent coating
US20020099438A1 (en) 1998-04-15 2002-07-25 Furst Joseph G. Irradiated stent coating
US8070796B2 (en) 1998-07-27 2011-12-06 Icon Interventional Systems, Inc. Thrombosis inhibiting graft
US7967855B2 (en) * 1998-07-27 2011-06-28 Icon Interventional Systems, Inc. Coated medical device
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
CA2424029C (en) † 2000-09-29 2008-01-29 Cordis Corporation Coated medical devices
US20040241211A9 (en) * 2000-11-06 2004-12-02 Fischell Robert E. Devices and methods for reducing scar tissue formation
US6534693B2 (en) * 2000-11-06 2003-03-18 Afmedica, Inc. Surgically implanted devices having reduced scar tissue formation
US20050084514A1 (en) * 2000-11-06 2005-04-21 Afmedica, Inc. Combination drug therapy for reducing scar tissue formation
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
US7763769B2 (en) 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
US6808518B2 (en) * 2001-09-28 2004-10-26 Ethicon, Inc. Methods and devices for treating diseased blood vessels
US8740973B2 (en) * 2001-10-26 2014-06-03 Icon Medical Corp. Polymer biodegradable medical device
US20030163144A1 (en) * 2002-02-28 2003-08-28 Weadock Kevin S. Sponge for creating an anastomosis between vessels
JP4265888B2 (ja) * 2002-06-12 2009-05-20 株式会社リコー 画像形成装置
US7361368B2 (en) * 2002-06-28 2008-04-22 Advanced Cardiovascular Systems, Inc. Device and method for combining a treatment agent and a gel
CA2495081A1 (en) * 2002-07-02 2004-01-15 Polycord, Inc. Polymerized and modified rapamycins and their use in coating medical prostheses
AU2003248847A1 (en) * 2002-07-09 2004-01-23 Eva Corporation Delivery apparatus for use during a surgical procedure and method of using the same
US8016881B2 (en) * 2002-07-31 2011-09-13 Icon Interventional Systems, Inc. Sutures and surgical staples for anastamoses, wound closures, and surgical closures
US20050163821A1 (en) * 2002-08-02 2005-07-28 Hsing-Wen Sung Drug-eluting Biodegradable Stent and Delivery Means
US7438925B2 (en) 2002-08-26 2008-10-21 Biovention Holdings Ltd. Drug eluting coatings for medical implants
AU2003218077B2 (en) * 2002-09-06 2009-10-08 Abbott Laboratories Medical device having hydration inhibitor
AU2003272471B2 (en) 2002-09-18 2010-10-07 Trustees Of The University Of Pennsylvania Method of inhibiting choroidal neovascularization
US20040146546A1 (en) * 2002-09-26 2004-07-29 Angiotech Pharmaceuticals, Inc. Perivascular wraps
AU2002953440A0 (en) * 2002-12-19 2003-01-09 Unisearch Limited A method of treating a stiffened vessel
US20050233030A1 (en) 2004-03-10 2005-10-20 Broin And Associates, Inc. Methods and systems for producing ethanol using raw starch and fractionation
CA2517920C (en) * 2003-03-10 2012-12-18 Broin And Associates, Inc. Method for producing ethanol using raw starch
EP1460088A1 (en) 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
US8821473B2 (en) 2003-04-15 2014-09-02 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
US7641643B2 (en) 2003-04-15 2010-01-05 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
CA2529754C (en) * 2003-06-19 2016-05-10 Vascular Therapies Llc Medical devices and methods for regulating the tissue response to vascular closure devices
US20050181977A1 (en) * 2003-11-10 2005-08-18 Angiotech International Ag Medical implants and anti-scarring agents
US7553326B2 (en) 2003-11-24 2009-06-30 Sweet Richard M Method and apparatus for preventing dialysis graft intimal hyperplasia
US7211108B2 (en) * 2004-01-23 2007-05-01 Icon Medical Corp. Vascular grafts with amphiphilic block copolymer coatings
US20050239181A1 (en) * 2004-03-10 2005-10-27 Broin And Associates, Inc. Continuous process for producing ethanol using raw starch
US8431145B2 (en) * 2004-03-19 2013-04-30 Abbott Laboratories Multiple drug delivery from a balloon and a prosthesis
US20070027523A1 (en) * 2004-03-19 2007-02-01 Toner John L Method of treating vascular disease at a bifurcated vessel using coated balloon
ATE534424T1 (de) * 2004-03-19 2011-12-15 Abbott Lab Mehrfache arzneiabgabe aus einem ballon und eine prothese
US20100030183A1 (en) * 2004-03-19 2010-02-04 Toner John L Method of treating vascular disease at a bifurcated vessel using a coated balloon
US7857767B2 (en) * 2004-04-19 2010-12-28 Invention Science Fund I, Llc Lumen-traveling device
KR100596218B1 (ko) * 2004-06-10 2006-07-03 (주)액세스 플러스 약물이 표면처리된 혈액투석환자의 동정맥 연결용 튜브
US20060009839A1 (en) * 2004-07-12 2006-01-12 Scimed Life Systems, Inc. Composite vascular graft including bioactive agent coating and biodegradable sheath
US8236338B2 (en) * 2004-07-13 2012-08-07 The University Of Tennessee Research Foundation Adhesive composition for carrying therapeutic agents as delivery vehicle on coatings applied to vascular grafts
US11207457B2 (en) 2004-08-27 2021-12-28 Edwards Lifesciences Corporation Device and method for establishing an artificial arterio-venous fistula
CA2577108A1 (en) 2004-08-31 2006-03-09 C.R. Bard, Inc. Self-sealing ptfe graft with kink resistance
US20060069426A1 (en) * 2004-09-27 2006-03-30 Weinberger Judah Z Methods and devices for extravascular intervention
US20060106406A1 (en) * 2004-09-27 2006-05-18 Judah Weinberger Methods and devices for extravascular intervention
US20060135970A1 (en) 2004-11-15 2006-06-22 Laurent Schaller Catheter-based tissue remodeling devices and methods
US7993738B2 (en) * 2004-11-30 2011-08-09 The Regents Of The University Of Michigan Modified porous materials and method of forming the same
WO2006062909A2 (en) * 2004-12-08 2006-06-15 Pervasis Therapeutics, Inc. Methods and compositions for enhancing vascular access
CN101940801B (zh) * 2004-12-08 2014-04-16 夏尔再生医学公司 增强血管通路的方法和组合物
AU2006213673A1 (en) 2005-02-09 2006-08-17 Santen Pharmaceutical Co., Ltd. Formulations for ocular treatment
US20060264914A1 (en) * 2005-03-03 2006-11-23 Icon Medical Corp. Metal alloys for medical devices
US20060201601A1 (en) * 2005-03-03 2006-09-14 Icon Interventional Systems, Inc. Flexible markers
EP1858440B1 (en) * 2005-03-03 2024-04-24 MiRus LLC Improved metal alloys for medical device
US9107899B2 (en) 2005-03-03 2015-08-18 Icon Medical Corporation Metal alloys for medical devices
US7540995B2 (en) 2005-03-03 2009-06-02 Icon Medical Corp. Process for forming an improved metal alloy stent
US8323333B2 (en) * 2005-03-03 2012-12-04 Icon Medical Corp. Fragile structure protective coating
WO2006110197A2 (en) * 2005-03-03 2006-10-19 Icon Medical Corp. Polymer biodegradable medical device
JP5242374B2 (ja) * 2005-03-23 2013-07-24 アボット・ラボラトリーズ 組成物ならびに長期効力を得るための医療機器を用いたラパマイシン類縁体の投与方法
US8828433B2 (en) * 2005-04-19 2014-09-09 Advanced Cardiovascular Systems, Inc. Hydrogel bioscaffoldings and biomedical device coatings
US20080125745A1 (en) 2005-04-19 2008-05-29 Shubhayu Basu Methods and compositions for treating post-cardial infarction damage
US9539410B2 (en) 2005-04-19 2017-01-10 Abbott Cardiovascular Systems Inc. Methods and compositions for treating post-cardial infarction damage
CN101268183B (zh) * 2005-04-21 2011-11-30 麻省理工学院 改变对外源和内源免疫原（包括同系和非同系细胞、组织或器官）的免疫应答的材料和方法
US8333777B2 (en) 2005-04-22 2012-12-18 Benvenue Medical, Inc. Catheter-based tissue remodeling devices and methods
US20070037267A1 (en) * 2005-05-02 2007-02-15 Broin And Associates, Inc. Methods and systems for producing ethanol using raw starch and fractionation
US8002738B2 (en) * 2005-05-17 2011-08-23 Boston Scientific Scimed, Inc. Self-adhering lesion formation apparatus and methods
JP2008543376A (ja) * 2005-06-08 2008-12-04 シー・アール・バード・インコーポレーテッド 無機生体適合性カルシウム塩を有するグラフト及びステント
EP1890641B1 (en) 2005-06-17 2017-04-19 C.R. Bard, Inc. Vascular graft with kink resistance after clamping
AU2006262682B2 (en) 2005-06-21 2012-07-05 Shire Regenerative Medicine, Inc. Methods and compositions for enhancing vascular access
US20100268321A1 (en) * 2005-09-06 2010-10-21 C R Bard, Inc. Drug-releasing graft
US7219021B2 (en) * 2005-09-13 2007-05-15 Honeywell International Inc. Multiple wireless sensors for dialysis application
US7919289B2 (en) * 2005-10-10 2011-04-05 Poet Research, Inc. Methods and systems for producing ethanol using raw starch and selecting plant material
JP5285426B2 (ja) * 2005-10-14 2013-09-11 アボット ラボラトリーズ 医療デバイスを用いて、パクリタキセルとともにラパマイシン類似体を投与することについての組成物、システム、キット及び方法
WO2007056761A2 (en) 2005-11-09 2007-05-18 C.R. Bard Inc. Grafts and stent grafts having a radiopaque marker
EP1948079A1 (en) * 2005-11-17 2008-07-30 Access Plus Co., Ltd. A tube for connecting marteriovenous and interposition for medical operation
US20100204783A1 (en) * 2005-12-06 2010-08-12 Helen Marie Nugent Methods and compositions for enhancing vascular access
BRPI0600275A (pt) * 2006-01-03 2007-10-02 Brz Biotecnologia Ltda prótese coronária liberadora de composição medicamentosa para prevenção e tratamento da reestenose e processo de fabricação
CA2635797C (en) 2006-02-09 2015-03-31 Macusight, Inc. Stable formulations, and methods of their preparation and use
US8828077B2 (en) * 2006-03-15 2014-09-09 Medinol Ltd. Flat process of preparing drug eluting stents
JP5506378B2 (ja) 2006-03-23 2014-05-28 参天製薬株式会社 血管透過性に関連する疾患または病気のための製剤および方法
US8550344B2 (en) * 2006-06-16 2013-10-08 The Invention Science Fund I, Llc Specialty stents with flow control features or the like
US8478437B2 (en) 2006-06-16 2013-07-02 The Invention Science Fund I, Llc Methods and systems for making a blood vessel sleeve
US7818084B2 (en) * 2006-06-16 2010-10-19 The Invention Science Fund, I, LLC Methods and systems for making a blood vessel sleeve
US8551155B2 (en) * 2006-06-16 2013-10-08 The Invention Science Fund I, Llc Stent customization system and method
US8147537B2 (en) * 2006-06-16 2012-04-03 The Invention Science Fund I, Llc Rapid-prototyped custom-fitted blood vessel sleeve
US20080172073A1 (en) * 2006-06-16 2008-07-17 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Active blood vessel sleeve
US8163003B2 (en) * 2006-06-16 2012-04-24 The Invention Science Fund I, Llc Active blood vessel sleeve methods and systems
US8095382B2 (en) * 2006-06-16 2012-01-10 The Invention Science Fund I, Llc Methods and systems for specifying a blood vessel sleeve
US20080133040A1 (en) * 2006-06-16 2008-06-05 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for specifying a blood vessel sleeve
US20090024152A1 (en) * 2007-07-17 2009-01-22 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Custom-fitted blood vessel sleeve
US7722665B2 (en) 2006-07-07 2010-05-25 Graft Technologies, Inc. System and method for providing a graft in a vascular environment
WO2008008291A2 (en) * 2006-07-13 2008-01-17 Icon Medical Corp. Stent
US20080039362A1 (en) * 2006-08-09 2008-02-14 Afmedica, Inc. Combination drug therapy for reducing scar tissue formation
US20080077070A1 (en) * 2006-08-10 2008-03-27 Kopia Gregory A Arteriovenous shunt
US9242005B1 (en) 2006-08-21 2016-01-26 Abbott Cardiovascular Systems Inc. Pro-healing agent formulation compositions, methods and treatments
US20080085293A1 (en) * 2006-08-22 2008-04-10 Jenchen Yang Drug eluting stent and therapeutic methods using c-Jun N-terminal kinase inhibitor
WO2008026644A1 (fr) * 2006-08-29 2008-03-06 Fujifilm Corporation Matrice hydrophile ayant un composé faiblement soluble dans l'eau scellé à l'intérieur de celle-ci et procédé pour produire celle-ci
US9198749B2 (en) 2006-10-12 2015-12-01 C. R. Bard, Inc. Vascular grafts with multiple channels and methods for making
AU2007317789B2 (en) * 2006-11-07 2011-02-10 Shire Regenerative Medicine, Inc. Materials and methods for treating and managing angiogenesis-mediated diseases
US9005672B2 (en) 2006-11-17 2015-04-14 Abbott Cardiovascular Systems Inc. Methods of modifying myocardial infarction expansion
US8741326B2 (en) * 2006-11-17 2014-06-03 Abbott Cardiovascular Systems Inc. Modified two-component gelation systems, methods of use and methods of manufacture
US8192760B2 (en) 2006-12-04 2012-06-05 Abbott Cardiovascular Systems Inc. Methods and compositions for treating tissue using silk proteins
US8177798B2 (en) 2006-12-05 2012-05-15 Tyco Healthcare Group Lp Adhesive coated stent and insertion instrument
WO2008156705A1 (en) * 2007-06-13 2008-12-24 Pervasis Therapeutics, Inc. Methods and devices for minimally-invasive delivery of cell-containing flowable compositions
US10004507B2 (en) 2007-06-18 2018-06-26 Asfora Ip, Llc Vascular anastomosis device and method
US8361092B1 (en) 2007-06-18 2013-01-29 Wilson T. Asfora Vascular anastomosis device and method
US9504469B2 (en) 2007-06-18 2016-11-29 Asfora Ip, Llc Vascular anastomosis device and method
US8721711B2 (en) * 2007-06-20 2014-05-13 Oregon Health & Science University Graft having microporous membrane for uniform fluid infusion
WO2009073782A2 (en) * 2007-12-04 2009-06-11 Ams Research Corporation Apparatus and methods for treatment of pathologic proliferative conditions of uterine tissue
US8808255B2 (en) * 2007-12-14 2014-08-19 Oregon Health & Science University Drug delivery cuff
EP2268302B1 (en) * 2008-02-13 2014-04-09 Keith Hruska Bmp-7 for use in treating neointimal hyperplasia
CN102027018A (zh) 2008-03-13 2011-04-20 生物测试股份公司 一种治疗疾病的试剂
CN102027016A (zh) 2008-03-13 2011-04-20 生物测试股份公司 一种治疗疾病的试剂
CA2718184A1 (en) 2008-03-13 2009-10-08 Biotest Ag Agent for treating disease
US20090264906A1 (en) * 2008-04-22 2009-10-22 Medtronic Vascular, Inc. Cuff Device
EP2257322A1 (en) * 2008-05-16 2010-12-08 David Chang Method and apparatus for vascular access
DK2341937T3 (en) * 2008-09-29 2015-02-09 Biotest Ag Composition for the treatment of a disease
KR101034654B1 (ko) * 2009-01-15 2011-05-16 성균관대학교산학협력단 바이오액티브 물질 코팅방법
US8450094B1 (en) 2009-03-03 2013-05-28 Poet Research, Inc. System for management of yeast to facilitate the production of ethanol
WO2010102060A2 (en) * 2009-03-03 2010-09-10 Poet Research, Inc. System for pre-treatment of biomass for the production of ethanol
HUE025623T2 (en) 2009-03-03 2016-04-28 Poet Res Inc A method of fermenting biomass for ethanol production
US9068206B1 (en) 2009-03-03 2015-06-30 Poet Research, Inc. System for treatment of biomass to facilitate the production of ethanol
US20100233266A1 (en) 2009-03-13 2010-09-16 Cleek Robert L Articles and methods of treating vascular conditions
CA2759266C (en) * 2009-04-20 2015-10-20 Rox Medical, Inc. Device and method for establishing an artificial arterio-venous fistula
US8597262B2 (en) * 2009-07-09 2013-12-03 Ams Research Corporation Apparatus and methods of treatment of pathologic proliferative conditions uterine tissue
JP2011528608A (ja) * 2009-09-29 2011-11-24 エム． アイ． テック カンパニー， インコーポレイテッド 移植用チューブおよびそのコーティング方法
WO2011063462A1 (en) 2009-11-27 2011-06-03 Stephen Anthony Livesey A method of inducing cellular growth and materials for use therewith
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
US8951595B2 (en) * 2009-12-11 2015-02-10 Abbott Cardiovascular Systems Inc. Coatings with tunable molecular architecture for drug-coated balloon
US8480620B2 (en) * 2009-12-11 2013-07-09 Abbott Cardiovascular Systems Inc. Coatings with tunable solubility profile for drug-coated balloon
US20110144577A1 (en) * 2009-12-11 2011-06-16 John Stankus Hydrophilic coatings with tunable composition for drug coated balloon
US8900603B2 (en) 2009-12-18 2014-12-02 Interface Biologics, Inc. Local delivery of drugs from self assembled coatings
JP2011130989A (ja) * 2009-12-25 2011-07-07 Japan Health Science Foundation 抗血栓性修飾剤、医療用具、及び、多孔質コラーゲン
AU2010339379B2 (en) * 2009-12-30 2014-02-06 Caliber Therapeutics, Llc Balloon catheter systems for delivery of dry drug delivery vesicles to a vessel in the body
WO2011090224A1 (ko) * 2010-01-21 2011-07-28 서울대학교산학협력단 의료용 품물의 약물 코팅 방법
WO2011094459A1 (en) * 2010-01-27 2011-08-04 Iyer Sriram S Device and method for preventing stenosis at an anastomosis site
US8974519B2 (en) 2010-02-19 2015-03-10 Cardiovascular Systems, Inc. Therapeutic agent delivery system, device and method for localized application of therapeutic substances to a biological conduit
US8398916B2 (en) 2010-03-04 2013-03-19 Icon Medical Corp. Method for forming a tubular medical device
EP2544623B1 (en) * 2010-03-09 2018-01-10 Solinas Medical Inc. Self-closing devices
IT1400232B1 (it) * 2010-05-07 2013-05-24 Advance Holdings Ltd Composizione farmaceutica topica comprendente eparina
SG10201606406PA (en) * 2011-04-28 2016-09-29 Abraxis Bioscience Llc Intravascular delivery of nanoparticle compositions and uses thereof
US10350431B2 (en) * 2011-04-28 2019-07-16 Gt Medical Technologies, Inc. Customizable radioactive carriers and loading system
US20140186310A1 (en) * 2011-05-26 2014-07-03 Kathy Traianedes Method of ex vivo cellular growth
US8577693B2 (en) 2011-07-13 2013-11-05 The Invention Science Fund I, Llc Specialty stents with flow control features or the like
US9433722B2 (en) * 2011-08-09 2016-09-06 Abbott Cardiovascular Systems Inc. Vascular shield and delivery system
PL3255106T3 (pl) 2012-01-09 2019-09-30 Innocoll Pharmaceuticals Limited Zmodyfikowany kolagen
US20130303983A1 (en) * 2012-05-09 2013-11-14 Cook Medical Technologies Llc Coated medical devices including a water-insoluble therapeutic agent
AU2013338051C1 (en) 2012-10-29 2017-08-10 Ariste Medical, Llc. Polymer coating compositions and coated products
WO2014127278A2 (en) * 2013-02-18 2014-08-21 Elutin, Inc. Site specific drug delivery wraps, systems and methods of use thereof
US9492683B2 (en) 2013-03-15 2016-11-15 Gammatile Llc Dosimetrically customizable brachytherapy carriers and methods thereof in the treatment of tumors
US20150119908A1 (en) * 2013-10-25 2015-04-30 Abbott Cardiovascular Systems Inc. Extravascular devices supporting an arteriovenous fistula
US20150119976A1 (en) * 2013-10-29 2015-04-30 Abbott Cardiovascular Systems Inc. Extravascular device for limiting blood flow adjacent an arteriovenous fistula
US9687239B2 (en) 2014-04-15 2017-06-27 Abbott Cardiovascular Systems Inc. Intravascular devices supporting an arteriovenous fistula
WO2015164524A1 (en) 2014-04-22 2015-10-29 Ariste Medical, Inc. Methods and processes for application of drug delivery polymeric coatings
CN106535826A (zh) 2014-06-24 2017-03-22 怡康医疗股份有限公司 用于医疗装置的改进的金属合金
US20160193390A1 (en) * 2015-01-05 2016-07-07 Wisconsin Alumni Research Foundation Perivascular Delivery System And Method
EP3250277B1 (en) * 2015-01-26 2022-09-21 Mercator Medsystems, Inc. Methods and systems for inhibiting vascular inflammation
US9821174B1 (en) 2015-02-06 2017-11-21 Gammatile Llc Radioactive implant planning system and placement guide system
EP3078349B1 (en) * 2015-04-10 2019-06-19 Cook Medical Technologies LLC Prosthesis with fenestration
WO2017151548A1 (en) 2016-03-04 2017-09-08 Mirus Llc Stent device for spinal fusion
US10888710B1 (en) 2016-11-29 2021-01-12 Gt Medical Technologies, Inc. Transparent loading apparatus
EP3796948A4 (en) 2018-05-22 2022-03-02 Interface Biologics Inc. COMPOSITIONS AND METHODS FOR ADMINISTRATION OF MEDICATIONS TO A VESSEL WALL
DE102018127200B3 (de) * 2018-10-31 2019-07-25 Andreas Haas Implantat zum subkutanen implantieren
CN111012409A (zh) * 2019-12-03 2020-04-17 王超 颞浅动脉额支与脑动脉皮层血运重建辅助三通及使用方法
CN114259607B (zh) * 2021-12-28 2023-01-24 宇航 一种支架制备方法
WO2024068159A1 (en) 2022-09-30 2024-04-04 Biotronik Ag Synthesis and characterization of cyclic hydrocarbon esters of everolimus
WO2024068153A1 (en) 2022-09-30 2024-04-04 Biotronik Ag Macrocyclic triene immunosuppressive compounds for perivascular medical treatment of vascular access fistulas, grafts and other vascular conditions

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU471719A3 (ru) 1969-07-19 1975-05-25 Шеринг Аг (Фирма) Способ получени нитрофуриламиноалкоксипиримидина
US3797485A (en) 1971-03-26 1974-03-19 Alza Corp Novel drug delivery device for administering drug into blood circulation in blood vessel
US4391797A (en) 1977-01-05 1983-07-05 The Children's Hospital Medical Center Systems for the controlled release of macromolecules
US4164559A (en) 1977-09-21 1979-08-14 Cornell Research Foundation, Inc. Collagen drug delivery device
US4409332A (en) 1982-01-12 1983-10-11 Jefferies Steven R Collagen-enzyme conjugates that exhibit no inflammatory response and method for making the same
US4677120A (en) 1985-07-31 1987-06-30 Molecular Design International Topical prodrugs for treatment of acne and skin diseases
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
US4889842A (en) 1987-03-03 1989-12-26 Morris Randall E Concanavalin A dimers as therapeutic agents
US5124356A (en) 1987-06-29 1992-06-23 Molecular Design International, Inc. Dermal uses of trans-retinoids for the treatment of photoaging
US4885311A (en) 1987-06-29 1989-12-05 Molecular Design International Topical transretinoids for treatment of acne and skin diseases
US4994491A (en) 1988-12-14 1991-02-19 Molecular Design International Dermal uses of trans-retinoids for the treatment of cancer
US4840940A (en) 1987-10-21 1989-06-20 Sottiurai Vikrom S Method for reducing the occurrence of distal anastomotic intimal hyperplasia using fractionated heparin
US5157049A (en) 1988-03-07 1992-10-20 The United States Of America As Represented By The Department Of Health & Human Services Method of treating cancers sensitive to treatment with water soluble derivatives of taxol
US5100668A (en) 1988-06-14 1992-03-31 Massachusetts Institute Of Technology Controlled release systems containing heparin and growth factors
US5074869A (en) * 1988-09-26 1991-12-24 Daicoff George R Vascular occlusion device
US5049584A (en) 1988-12-14 1991-09-17 Molecular Design International Dermal uses of cis-retinoids for the treatment of cancer
US5223269A (en) 1989-08-31 1993-06-29 Andrejs Liepins Methods and composition for the treatment of hypertension
US6326017B1 (en) 1989-10-02 2001-12-04 University Of Washington Methods for the localized delivery of agents to blood vessels
WO1991007154A1 (en) 1989-11-13 1991-05-30 President And Fellows Of Harvard College EXTRALUMINAL REGULATION OF THE GROWTH AND REPAIR OF TUBULAR STRUCTURES ιIN VIVO
US5527532A (en) * 1989-11-13 1996-06-18 President And Fellows Of Harvard College Extraluminal regulation of the growth and repair of tubular structures in vivo
US5540928A (en) 1991-02-27 1996-07-30 President And Fellows Of Harvard College Extraluminal regulation of the growth and repair of tubular structures in vivo
US5138051A (en) 1991-08-07 1992-08-11 American Home Products Corporation Rapamycin analogs as immunosuppressants and antifungals
CA2082411A1 (en) 1991-06-28 1992-12-29 Robert D. Rosenberg Localized oligonucleotide therapy
US5169851A (en) 1991-08-07 1992-12-08 American Home Products Corporation Rapamycin analog as immunosuppressants and antifungals
US5202332A (en) 1991-08-07 1993-04-13 American Home Products Corporation Rapamycin analog as immunosuppressant
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
EP0539237A1 (en) 1991-10-25 1993-04-28 Cook Incorporated Expandable transluminal graft prosthesis for repair of aneurysm and method for implanting
US5516781A (en) 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
IT1254915B (it) * 1992-04-24 1995-10-11 Gloria Cristalli Derivati di adenosina ad attivita' a2 agonista
US5288711A (en) 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
WO1993023013A1 (en) 1992-05-20 1993-11-25 New England Deaconess Hospital Extravascular system for infusion of soluble substances
US5283257A (en) 1992-07-10 1994-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of treating hyperproliferative vascular disease
CA2086874E (en) 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5480988A (en) 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
CA2092271C (en) 1993-03-09 2009-10-13 Eddie Reed Use of g-csf for treating taxol side-effects
US5703247A (en) 1993-03-11 1997-12-30 Virginia Tech Intellectual Properties, Inc. 2-Debenzoyl-2-acyl taxol derivatives and methods for making same
US5571800A (en) 1993-05-17 1996-11-05 Azura, Inc. Method for inhibiting allograft rejection by the administration of 6-azauridine or its triacetate derivative
ATE264316T1 (de) 1993-06-11 2004-04-15 Upjohn Co Delta 6,7-taxol derivate antineoplastische verwendung und diese enthaltende pharmazeutische zusammenstellungen
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
DK1118325T4 (da) 1993-07-29 2010-04-06 Us Health Anvendelse af paclitaxel og dets derivater ved fremstilling af et medikament til behandling af restenose
US6323184B1 (en) 1993-10-15 2001-11-27 Thomas Jefferson University Arteriovenous and venous graft treatments: methods and compositions
US5519042A (en) 1994-01-13 1996-05-21 Hoechst Aktiengesellschaft Method of treating hyperproliferative vascular disease
IL127598A (en) 1994-01-28 2003-04-10 Upjohn Co Process for preparing isotaxol analogs
DE69524501T2 (de) 1994-08-12 2002-05-29 Meadox Medicals Inc Mit einen Heparin enhaltendes Kollagendichtmittel imprägniertes Gefässtransplantat
US5660873A (en) 1994-09-09 1997-08-26 Bioseal, Limited Liability Corporaton Coating intraluminal stents
US5616680A (en) * 1994-10-04 1997-04-01 Hoechst Celanese Corporation Process for producing liquid crystal polymer
US5837728A (en) 1995-01-27 1998-11-17 Molecular Design International 9-cis retinoic acid esters and amides and uses thereof
US5766584A (en) 1995-06-02 1998-06-16 Massachusetts Institute Of Technology Inhibition of vascular smooth muscle cell proliferation with implanted matrix containing vascular endothelial cells
US5780653A (en) 1995-06-07 1998-07-14 Vivorx Pharmaceuticals, Inc. Nitrophenyl, 10-deacetylated substituted taxol derivatives as dual functional cytotoxic/radiosensitizers
CA2178541C (en) 1995-06-07 2009-11-24 Neal E. Fearnot Implantable medical device
EP0871620A4 (en) 1995-09-11 1999-10-27 Enzymed Inc BIOCATALYTIC METHODS FOR SYTHESIS AND IDENTIFICATION OF BIOLOGICALLY ACTIVE COMPOUNDS
US5795286A (en) * 1996-08-15 1998-08-18 Cathco, Inc. Radioisotope impregnated sheet of biocompatible material for preventing scar tissue formation
CZ54899A3 (cs) 1996-08-23 1999-08-11 Cook Biotech, Incorporated Štěpová protéza, materiály s ní spojené a způsoby její výroby
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US6090996A (en) 1997-08-04 2000-07-18 Collagen Matrix, Inc. Implant matrix
US6015815A (en) 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
US6117166A (en) 1997-10-27 2000-09-12 Winston; Thomas R. Apparatus and methods for grafting blood vessel tissue
US6224794B1 (en) 1998-05-06 2001-05-01 Angiotech Pharmaceuticals, Inc. Methods for microsphere production
US6179858B1 (en) 1998-05-12 2001-01-30 Massachusetts Institute Of Technology Stent expansion and apposition sensing
US6091980A (en) 1998-05-12 2000-07-18 Massachusetts Institute Of Technology Stent slip sensing system and method
CN1338943A (zh) * 1998-10-26 2002-03-06 路德维格癌症研究院 利用vegf－c或vegf－d基因或蛋白预防再狭窄
DE19849589C1 (de) 1998-10-27 2000-06-15 Glatt Process Technology Gmbh Fibrin-Gewebekleber-Formulierung und Verfahren zu dessen Herstellung
US6333347B1 (en) 1999-01-29 2001-12-25 Angiotech Pharmaceuticals & Advanced Research Tech Intrapericardial delivery of anti-microtubule agents
US6391333B1 (en) 1999-04-14 2002-05-21 Collagen Matrix, Inc. Oriented biopolymeric membrane
US6328762B1 (en) 1999-04-27 2001-12-11 Sulzer Biologics, Inc. Prosthetic grafts
CA2396628A1 (en) 2000-01-25 2001-08-02 Edwards Lifesciences Corporation Delivery systems for treatment of restenosis and anastomotic intimal hyperplasia
US6746773B2 (en) 2000-09-29 2004-06-08 Ethicon, Inc. Coatings for medical devices
US6534693B2 (en) * 2000-11-06 2003-03-18 Afmedica, Inc. Surgically implanted devices having reduced scar tissue formation
PE20091074A1 (es) 2007-12-13 2009-07-26 Bayer Healthcare Ag Triazolotriazinas y triazolopirazinas y su uso

Also Published As

Publication number Publication date
US20190201383A1 (en) 2019-07-04
NZ527046A (en) 2005-06-24
EP2314293A1 (en) 2011-04-27
MXPA03006315A (es) 2004-12-03
DE60237671D1 (de) 2010-10-28
ATE481097T1 (de) 2010-10-15
CN1492759A (zh) 2004-04-28
RU2003125357A (ru) 2005-03-10
US20040197409A1 (en) 2004-10-07
US6726923B2 (en) 2004-04-27
US8858982B2 (en) 2014-10-14
US10272073B2 (en) 2019-04-30
US20030113359A1 (en) 2003-06-19
WO2002062335A3 (en) 2002-12-27
ES2621652T3 (es) 2017-07-04
AP2003002828A0 (en) 2003-09-30
US20150209334A1 (en) 2015-07-30
BR0206464A (pt) 2005-01-18
DK2314293T3 (en) 2017-04-18
WO2002062335A2 (en) 2002-08-15
JP2009119257A (ja) 2009-06-04
EP1351681B1 (en) 2010-09-15
JP4584537B2 (ja) 2010-11-24
PT2314293T (pt) 2017-04-11
CA2434972C (en) 2010-06-08
EP2314293B1 (en) 2017-01-04
EP1351681A2 (en) 2003-10-15
RU2345719C2 (ru) 2009-02-10
US20080091263A1 (en) 2008-04-17
JP5748389B2 (ja) 2015-07-15
JP2004523537A (ja) 2004-08-05
AU2002249958B2 (en) 2007-11-08
CA2434972A1 (en) 2002-08-15
US7807191B2 (en) 2010-10-05

Similar Documents

Publication Publication Date Title
CY1119109T1 (el) Συσκευη που μπορει να εμφυτευθει που περιεχει υλικο μητρας που μπορει να απορροφηθει και ραπαμυκινη για την προληψη ή την θεραπεια αγγειο-πολλαπλασιαστικων ασθενειων
CY1110894T1 (el) Μεθοδοι για θεραπεια ή προληψη αγγειακης φλεγμονης χρησιμοποιωντας αναστολεα (-εις) απορροφησης στερολης
TW200518752A (en) Combinations of drugs for the treatment of neoplasms
WO2004006906A3 (en) Methods for the treatment of neoplasms
BRPI0508451A (pt) método de tratamento de linfoma não-hodgkin em um mamìfero, usos de uma combinação de cci-779 e rituximab e de uma combinação de um inibidor de mtor e rituximab, produtos contendo cci-779 e rituximab e um inibidor mtor e rituximab, embalagem farmacêutica, e, composição farmacêutica
EA200100572A1 (ru) Способ применения ингибитора циклооксигеназы-2 и одного или нескольких противоопухолевых лекарственных средств в качестве комбинированного способа лечебного воздействия при лечении неоплазии
DK0691130T3 (da) Anvendelse af rapamycin til fremstilling af et lægemiddel til forebyggelse og behandling af hyperproliferative vaskulære sygdomme, eventuelt i kombination med mycophenolsyre
CY1108765T1 (el) ΑΓΩΓΗ ME ΑΝΤΙΣΩΜΑΤΑ ANTI-ErbB2
ATE551996T1 (de) Behandlung oder prävention von diabetes mit cannabidiol
ATE302599T1 (de) Zubereitungen und verfahren zur behandlung oder prävention von krankheiten der körperpassagewege
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
CY1109525T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΑ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2 ΚΑΙ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΜΕ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
CY1107439T1 (el) Μεθοδοι προληψης και θεραπειας μολυνσης απο ιο του γενους flavivirus σε ζωα
DE69100282D1 (de) Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie.
CY1110162T1 (el) Φαρμακοτεχνικη μορφη και μεθοδοι για την αγωγη της θρομβοκυτταραιμιας
HUP0303917A2 (hu) Szterin abszorpció inhibitor(ok) kombinációi vérmódosítókkal és ezek alkalmazása vaszkuláris kondíciók kezelésére
WO2005011572A3 (en) Combination of drugs for the treatment of neoplasms
ATE239467T1 (de) Methode zur behandlung oder verhütung von interstitieller blasenentzundung
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
DE69303305D1 (de) Mittel zur Behandlung chronischer Ermüdungserscheinungen
DE60129552D1 (de) E-selectin zur behandlung oder vorbeugung von schlaganfall
BR9708037A (pt) Método para o tratamento de abuso de substância
HUP9903685A2 (hu) Olanzapin alkalmazása túlzott agresszivitás kezelésére szolgáló gyógyszerkészítmények előállítására
DE60043247D1 (de) Verwendung von Peroxidlipiden zur Vorbeugung und/oder Behandlung von irritierenden Effekten eines Wirkstoffes